Literature DB >> 2907647

The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics.

R Olbrich1, H Schanz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2907647     DOI： 10.1055/s-2007-1017021

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN： 0176-3679            Impact factor:   5.788


× No keyword cloud information.
  10 in total

1.  PAOPA, a potent analogue of Pro-Leu-glycinamide and allosteric modulator of the dopamine D2 receptor, prevents NMDA receptor antagonist (MK-801)-induced deficits in social interaction in the rat: implications for the treatment of negative symptoms in schizophrenia.

Authors:  Bailee Dyck; Kelly Guest; Christal Sookram; Dipannita Basu; Rodney Johnson; Ram K Mishra
Journal:  Schizophr Res       Date:  2010-10-30       Impact factor: 4.939

2.  An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics.

Authors:  R Olbrich; H Schanz
Journal:  J Neural Transm Gen Sect       Date:  1991

Review 3.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

4.  Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study.

Authors:  K Svensson; A Ekman; M F Piercey; W E Hoffmann; J T Lum; A Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-09       Impact factor: 3.000

Review 5.  Classics in Chemical Neuroscience: Aripiprazole.

Authors:  Austen B Casey; Clinton E Canal
Journal:  ACS Chem Neurosci       Date:  2017-04-13       Impact factor: 4.418

Review 6.  α2-Adrenoceptors are targets for antipsychotic drugs.

Authors:  Jan Brosda; Florian Jantschak; Heinz H Pertz
Journal:  Psychopharmacology (Berl)       Date:  2014-02-02       Impact factor: 4.530

Review 7.  Migraine.

Authors:  Michel D Ferrari; Peter J Goadsby; Rami Burstein; Tobias Kurth; Cenk Ayata; Andrew Charles; Messoud Ashina; Arn M J M van den Maagdenberg; David W Dodick
Journal:  Nat Rev Dis Primers       Date:  2022-01-13       Impact factor: 52.329

Review 8.  Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia.

Authors:  H J Möller; H M van Praag; B Aufdembrinke; P Bailey; T R Barnes; J Beck; H Bentsen; F X Eich; L Farrow; W W Fleischhacker
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

Review 9.  Efficacy and safety of aripiprazole in child and adolescent patients.

Authors:  Eiji Kirino
Journal:  Eur Child Adolesc Psychiatry       Date:  2012-03-25       Impact factor: 4.785

Review 10.  Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents.

Authors:  Eiji Kirino
Journal:  Adolesc Health Med Ther       Date:  2014-11-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.